Intent Solutions Announces New Advisory Board Member – David Gastfriend

David R. Gastfriend, M.D. to Bring Pharma-Tech Knowledge

 ATLANTA (January 17, 2017) – Intent Solutions™, creator of the breakthrough medical device technology TAD™, is excited to announce the appointment of David R. Gastfriend, M.D., Chief Architect of CONTINUUM, the American Society of Addiction Medicine’s (ASAM) standardized treatment software, to its Advisory Board. Gastfriend brings a vast wealth of pharma-tech experience from his work at Alkermes, Inc., where he supported gaining FDA approval of VIVITROL® for the treatment of alcohol and opioid dependence. Most recently, Gastfriend co-foundedDynamiCare Health, Inc., a technology start-up that focuses on incentivizing patients for compliance with treatments. As a clinical scientist in addiction, he will assist in helping Intent Solutions optimize TAD for improving patient adherence, as well as advise the company on leveraging the various stakeholders in the healthcare system to achieve change and improvements in patient outcomes. 

“In a national opioid epidemic, modern healthcare is desperate for ways to carefully manage patient adherence to opioids and other pain medications,” said Gastfriend, when speaking about how TAD can impact the pharma-tech community. “TAD is a brilliantly conceived and executed tool that literally can be placed in the pocket of the patient and precisely dispense the prescribed medication, in the right amount, at the right time, to the right patient.  This closes the loop between the patient, pharmacy, and prescriber better than any alternative.”

TAD, for “Take As Directed,” is a smart, mobile, medication dispenser that helps patients obtain better health outcomes. TAD, which can also record adherence data, shares information to a cloud database for analysis, reducing errors and simplifying date reconciliation for clinical trials.

“Intent Solutions has a broad role to play in modern medicine.  It can address medication adherence challenges in all disease states that involve patient motivational problems, risks of abuse and diversion, and just plain chronic care burdens of maintaining consistent self care,” said Gastfriend.  “TAD stands to become a breakthrough in pharmacologic research, including FDA trials, ensuring that medicines being studied are truly being taken by patients as intended.  This is a huge unknown, currently, for which we have poor methods of validation, and yet it can make or break an otherwise excellent new treatment.”

For more information, visit  or contact